Merck & Co., Inc. is 2.7x more valuable than VERTEX PHARMACEUTICALS INC / MA by market capitalization ($293.16 B vs $110.46 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRTX | MRK |
|---|---|---|
| Market cap | $110.46 B | $293.16 B |
| US-listed rank | #136 | #44 |
| Revenue (latest FY) | $12.00B | $65.01B |
| Net income (latest FY) | $3.95B | $18.25B |
| Net margin | 32.9% | 28.1% |
| P/E (trailing FY) | 27.9 | 16.1 |
| SEC filings | 1,000 | 996 |
Merck & Co., Inc. is 2.7x more valuable than VERTEX PHARMACEUTICALS INC / MA by market capitalization ($293.16 B vs $110.46 B).
In their latest fiscal years, VERTEX PHARMACEUTICALS INC / MA reported $12.00B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: VERTEX PHARMACEUTICALS INC / MA and Merck & Co., Inc., or browse the full rankings.